Patents by Inventor Girish Sahni
Girish Sahni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11732016Abstract: The present disclosure relates to a polypeptide exhibiting granulocyte-colony stimulating factor activity. The polypeptide comprises at least one non-native cysteine residue at a site selected from the group consisting of T1CP2 (SEQ ID NO: 25), P2CL3 (SEQ ID NO: 26), L3CG4 (SEQ ID NO: 27), G4CP5 (SEQ ID NO: 28), P5CA6 (SEQ ID NO: 29), A6CS7 (SEQ ID NO: 30), S96CP97 (SEQ ID NO: 31), P97CE98 (SEQ ID NO: 32), L99CG100 (SEQ ID NO: 33), P101CT102 (SEQ ID NO: 34), E122CE123 (SEQ ID NO: 35), L124CG125 (SEQ ID NO: 36), M126CA127 (SEQ ID NO: 37), P138CA139 (SEQ ID NO: 39), A143CF144 (SEQ ID NO: 40), R146CR147 (SEQ ID NO: 41), R169CH170 (SEQ ID NO: 42), H170CL171 (SEQ ID NO: 43), L171CA172 (SEQ ID NO: 44), A172CQ173 (SEQ ID NO: 45), and Q173CP174 (SEQ ID NO: 46) in an amino acid sequence having at least 90% sequence identity to sequence set forth in SEQ ID NO: 2.Type: GrantFiled: December 24, 2018Date of Patent: August 22, 2023Assignee: Council of Scientific & Industrial ResearchInventors: Sonal Datta, Girish Sahni
-
Publication number: 20220096608Abstract: The present invention discloses modified forms of plasmin with advantageous properties. As compared to their natural unmodified form, these variants exhibit significantly modulated kinetics in terms of delayed inhibition characteristics in the presence of specific inhibitors, such as ?2-antiplasmin (?2-AP). These include PEG-conjugated thiol derivatives of truncated plasmin with potential clinical applications in various regimens of thrombolytic therapies.Type: ApplicationFiled: January 23, 2020Publication date: March 31, 2022Inventors: Navneet Kaur, Prakash Kumar, Girish Sahni
-
Patent number: 11008370Abstract: Disclosed herein is an expression system for the production and secretion of biologically active clot-specific streptokinase (CSSK) protein in methylotrophic yeast. Yeast-expressed CSSK protein displays improved plasminogen activation and fibrin selectivity. Further disclosed are methylotrophic yeast transformed with at least one copy of functional cDNA sequence encoding CSSK adjunct with modified signal sequence which results in secretion of mature and correctly processed CSSK.Type: GrantFiled: October 26, 2016Date of Patent: May 18, 2021Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCHInventors: Girish Sahni, Kishore Kumar Joshi
-
Publication number: 20210009647Abstract: The present disclosure relates to a polypeptide exhibiting granulocyte-colony stimulating factor activity. The polypeptide comprises at least one non-native cysteine residue at a site selected from the group consisting of T1CP2 (SEQ ID NO: 25), P2CL3 (SEQ ID NO: 26), L3CG4 (SEQ ID NO: 27), G4CP5 (SEQ ID NO: 28), P5CA6 (SEQ ID NO: 29), A6CS7 (SEQ ID NO: 30), S96CP97 (SEQ ID NO: 31), P97CE98 (SEQ ID NO: 32), L99CG100 (SEQ ID NO: 33), P101CT102 (SEQ ID NO: 34), E122CE123 (SEQ ID NO: 35), L124CG125 (SEQ ID NO: 36), M126CA127 (SEQ ID NO: 37), P138CA139 (SEQ ID NO: 39), A143CF144 (SEQ ID NO: 40), R146CR147 (SEQ ID NO: 41), R169CH170 (SEQ ID NO: 42), H170CL171 (SEQ ID NO: 43), L171CA172 (SEQ ID NO: 44), A172CQ173 (SEQ ID NO: 45), and Q173CP174 (SEQ ID NO: 46) in an amino acid sequence having at least 90% sequence identity to sequence set forth in SEQ ID NO: 2.Type: ApplicationFiled: December 24, 2018Publication date: January 14, 2021Inventors: Sonal DATTA, Girish SAHNI
-
Patent number: 10738292Abstract: The present invention relates to a novel endoglucanase gene (GH5 family) from the soil metagenome. More specifically, this invention provides a recombinant plasmid and the recombinant hosts for the expression of novel gene sequence having cellulase activity. The cellulase in the invention has high specific activity towards ?-1,4 linkages in substrates such as carboxy-methyl cellulose and barley-?-glucan etc. This novel cellulase can have many industrial applications eg. food and feed industry, detergent, textile and biofuel industry etc.Type: GrantFiled: November 11, 2016Date of Patent: August 11, 2020Assignee: Council of Scientific & Industrial ResearchInventors: Roma Garg, Vijaya Brahma, Lata Verma, Girish Sahni
-
Publication number: 20180371442Abstract: The present invention relates to a novel endoglucanase gene (GH5 family) from the soil metagenome. More specifically, this invention provides a recombinant plasmid and the recombinant hosts for the expression of novel gene sequence having cellulase activity. The cellulase in the invention has high specific activity towards ?-1,4 linkages in substrates such as carboxy-methyl cellulose and barley-?-glucan etc. This novel cellulase can have many industrial applications eg. food and feed industry, detergent, textile and biofuel industry etc.Type: ApplicationFiled: November 11, 2016Publication date: December 27, 2018Applicant: Council of Scientific & Industrial ResearchInventors: Roma Garg, Vijaya Brahma, Lata Verma, Girish Sahni
-
A GENETICALLY MODIFIED YEAST CELL AND IMPROVED PROCESS FOR PRODUCTION OF CLOT-SPECIFIC STREPTOKINASE
Publication number: 20180362596Abstract: Disclosed herein is an expression system for the production and secretion of biologically active clot-specific streptokinase (CSSK) protein in methylotrophic yeast. Yeast-expressed CSSK protein displays improved plasminogen activation and fibrin selectivity. Further disclosed are methylotrophic yeast transformed with at least one copy of functional cDNA sequence encoding CSSK adjunct with modified signal sequence which results in secretion of mature and correctly processed CSSK.Type: ApplicationFiled: October 26, 2016Publication date: December 20, 2018Applicant: Council of Scientific & Industrial ResearchInventors: Girish Sahni, Kishore Kumar Joshi -
Patent number: 9695408Abstract: The present invention relates to novel mutants of Streptokinase, its functional fragments and covalently modified forms. Methods are provided for the preparation of the bacterial plasminogen activator protein, Streptokinase its muteins, species variants and their covalently modified variants that are characterized by improved therapeutic properties, such as increased proteolytic stability, extended plasma half-lives, reduced immuno-reactivity and enhanced fibrin clot specificity. The method involves either incorporating additional cysteine residues, or substituting cysteine residues for naturally occurring amino acids into non-essential regions of the protein such that the catalytic activity of the resultant protein remains largely unaltered. These cysteine variants were further modified by covalently attaching a cysteine reactive polymer such as polyethylene glycol (PEG) or sulfhydryl-reactive moieties from a group that includes fluorophore, spin labels or other small conjugates.Type: GrantFiled: August 19, 2015Date of Patent: July 4, 2017Assignee: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCHInventors: Shekhar Kumar, Neeraj Maheshwari, Girish Sahni
-
Publication number: 20150344861Abstract: The present invention relates to novel mutants of Streptokinase, its functional fragments and covalently modified forms. Methods are provided for the preparation of the bacterial plasminogen activator protein, Streptokinase its muteins, species variants and their covalently modified variants that are characterized by improved therapeutic properties, such as increased proteolytic stability, extended plasma half-lives, reduced immuno-reactivity and enhanced fibrin clot specificity. The method involves either incorporating additional cysteine residues, or substituting cysteine residues for naturally occurring amino acids into non-essential regions of the protein such that the catalytic activity of the resultant protein remains largely unaltered. These cysteine variants were further modified by covalently attaching a cysteine reactive polymer such as polyethylene glycol (PEG) or sulfhydryl-reactive moieties from a group that includes fluorophore, spin labels or other small conjugates.Type: ApplicationFiled: August 19, 2015Publication date: December 3, 2015Applicant: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCHInventors: Shekhar KUMAR, Neeraj MAHESHWARI, Girish SAHNI
-
Patent number: 9150844Abstract: The present invention discloses novel hybrid proteins that have both plasminogen activator and anti-thrombotic properties, including clot specific action, that renders these as highly advantageous for the treatment of circulatory disorders involving fibrin clot formation due to underlying tissue damage in the blood vessels leading to myocardial infarction, strokes etc. Also disclosed are new proteins, and methods of obtaining the same, that help to dissolve blood clots by activating plasminogen in a plasmin or thrombin dependent manner and also inhibit both the activity and generation of thrombin through the intrinsic pathway of blood coagulation.Type: GrantFiled: August 5, 2011Date of Patent: October 6, 2015Inventors: Neeraj Maheshwari, Girish Sahni
-
Patent number: 9115210Abstract: The present invention relates to novel mutants of Streptokinase, its functional fragments and covalently modified forms. Methods are provided for the preparation of the bacterial plasminogen activator protein, Streptokinase its muteins, species variants and their covalently modified variants that are characterized by improved therapeutic properties, such as increased proteolytic stability, extended plasma half-lives, reduced immuno-reactivity and enhanced fibrin clot specificity. The method involves either incorporating additional cysteine residues, or substituting cysteine residues for naturally occurring amino acids into non-essential regions of the protein such that the catalytic activity of the resultant protein remains largely unaltered. These cysteine variants were further modified by covalently attaching a cysteine reactive polymer such as polyethylene glycol (PEG) or sulfhydryl-reactive moieties from a group that includes fluorophore, spin labels or other small conjugates.Type: GrantFiled: December 6, 2011Date of Patent: August 25, 2015Assignee: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCHInventors: Shekhar Kumar, Neeraj Maheshwari, Girish Sahni
-
Publication number: 20130136731Abstract: The present invention discloses novel hybrid proteins that have both plasminogen activator and anti-thrombotic properties, including clot specific action, that renders these as highly advantageous for the treatment of circulatory disorders involving fibrin clot formation due to underlying tissue damage in the blood vessels leading to myocardial infarction, strokes etc. Also disclosed are new proteins, and methods of obtaining the same, that help to dissolve blood clots by activating plasminogen in a plasmin or thrombin dependent manner and also inhibit both the activity and generation of thrombin through the intrinsic pathway of blood coagulation.Type: ApplicationFiled: August 5, 2011Publication date: May 30, 2013Applicant: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCHInventors: Neeraj Maheshwari, Girish Sahni
-
Publication number: 20120213763Abstract: The present invention relates to novel mutants of Streptokinase, its functional fragments and covalently modified forms. Methods are provided for the preparation of the bacterial plasminogen activator protein, Streptokinase its muteins, species variants and their covalently modified variants that are characterized by improved therapeutic properties, such as increased proteolytic stability, extended plasma half-lives, reduced immuno-reactivity and enhanced fibrin clot specificity. The method involves either incorporating additional cysteine residues, or substituting cysteine residues for naturally occurring amino acids into non-essential regions of the protein such that the catalytic activity of the resultant protein remains largely unaltered. These cysteine variants were further modified by covalently attaching a cysteine reactive polymer such as polyethylene glycol (PEG) or sulfhydryl-reactive moieties from a group that includes fluorophore, spin labels or other small conjugates.Type: ApplicationFiled: December 6, 2011Publication date: August 23, 2012Applicant: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCHInventors: Shekhar KUMAR, Neeraj MAHESHWARI, Girish SAHNI
-
Patent number: 8143027Abstract: The present invention provides polynucleotides encoding clot-specific streptokinase proteins possessing altered plasminogen characteristics, including enhanced fibrin selectivity. The kinetics of plasminogen activation by these proteins are distinct from those of natural streptokinase, in that there is a temporary delay or lag in the initial rate of catalytic conversion of plasminogen to plasmin. Also disclosed are processes for preparing the proteins.Type: GrantFiled: July 23, 2007Date of Patent: March 27, 2012Assignee: Council of Scientific & Industrial Research of Rafi MargInventors: Girish Sahni, Rajesh Kumar, Chiati Roy, Kammara Rajagopal, Deepak Nihalani, Vasudha Sundaram, Mahavir Yadav
-
Patent number: 8093032Abstract: The present invention relates to novel mutants of Streptokinase, its functional fragments and covalently modified forms. Methods are provided for the preparation of the bacterial plasminogen activator protein, Streptokinase its muteins, species variants and their covalently modified variants that are characterized by improved therapeutic properties, such as increased proteolytic stability, extended plasma half-lives, reduced immuno-reactivity and enhanced fibrin clot specificity. The method involves either incorporating additional cysteine residues, or substituting cysteine residues for naturally occurring amino acids into non-essential regions of the protein such that the catalytic activity of the resultant protein remains largely unaltered. These cysteine variants were further modified by covalently attaching a cysteine reactive polymer such as polyethylene glycol (PEG) or sulfhydryl-reactive moieties from a group that includes fluorophore, spin labels or other small conjugates.Type: GrantFiled: March 31, 2009Date of Patent: January 10, 2012Assignee: Council of Scientific and Industrial ResearchInventors: Shekhar Kumar, Neeraj Maheshwari, Girish Sahni
-
Publication number: 20100034804Abstract: The present invention relates to novel mutants of Streptokinase, its functional fragments and covalently modified forms. Methods are provided for the preparation of the bacterial plasminogen activator protein, Streptokinase its muteins, species variants and their covalently modified variants that are characterized by improved therapeutic properties, such as increased proteolytic stability, extended plasma half-lives, reduced immuno-reactivity and enhanced fibrin clot specificity. The method involves either incorporating additional cysteine residues, or substituting cysteine residues for naturally occurring amino acids into non-essential regions of the protein such that the catalytic activity of the resultant protein remains largely unaltered. These cysteine variants were further modified by covalently attaching a cysteine reactive polymer such as polyethylene glycol (PEG) or sulfhydryl-reactive moieties from a group that includes fluorophore, spin labels or other small conjugates.Type: ApplicationFiled: March 31, 2009Publication date: February 11, 2010Inventors: Shekhar Kumar, Neeraj Maheshwari, Girish Sahni
-
Publication number: 20080171362Abstract: The present invention provides polynucleotides encoding clot-specific streptokinase proteins possessing altered plasminogen characteristics, including enhanced fibrin selectivity. The kinetics of plasminogen activation by these proteins are distinct from those of natural streptokinase, in that there is a temporary delay or lag in the initial rate of catalytic conversion of plasminogen to plasmin. Also disclosed are processes for preparing the proteins.Type: ApplicationFiled: July 23, 2007Publication date: July 17, 2008Inventors: Girish Sahni, Rajesh Kumar, Chiati Roy, Kammara Rajagopal, Deepak Nihalani, Vasudha Sundaram, Mahavir Yadav
-
Patent number: 7250503Abstract: The present invention provides polynucleotides encoding clot-specific streptokinase proteins possessing altered plasminogen characteristics, including enhanced fibrin selectivity. The kinetics of plasminogen activation by these proteins are distinct from those of natural streptokinase, in that there is a temporary delay or lag in the initial rate of catalytic conversion of plasminogen to plasmin. Also disclosed are processes for preparing the proteins.Type: GrantFiled: July 31, 2003Date of Patent: July 31, 2007Assignee: Council of Scientific and Industrial ResearchInventors: Girish Sahni, Rajesh Kumar, Chaiti Roy, Kammara Rajagopal, Deepak Nihalani, Vasudha Sundaram, Mahavir Yadav
-
Patent number: 7163817Abstract: The invention disclosed herein provides clot specific streptokinase proteins possessing altered plasminogen characteristics, including enhanced fibrin selectivity. The kinetics of plasminogen activation by these proteins are distinct from those of natural streptokinase, in that there is a temporary delay or lag in the initial rate of catalytic conversion of plasminogen to plasmin. Also disclosed are processes for preparing the proteins.Type: GrantFiled: August 27, 2001Date of Patent: January 16, 2007Inventors: Girish Sahni, Rajesh Kumar, Chaiti Roy, Kammara Rajagopal, Deepak Nihalani, Vasudha Sundaram, Mahavir Yadav
-
Publication number: 20050260598Abstract: Clot-specific streptokinase proteins possessing altered plasminogen characteristics, including enhanced fibrin selectivity. The kinetics of plasminogen activation by these proteins are distinct from those of natural streptokinase, in that there is a temporary delay or lag in the initial rate of catalytic conversion of plasminogen to plasmin. Also disclosed are processes for preparing the proteins.Type: ApplicationFiled: July 31, 2003Publication date: November 24, 2005Inventors: Girish Sahni, Rajesh Kumar, Chaiti Roy, Kammara Rajagopal, Deepak Nihalani, Vasudha Sundaram, Mahavir Yadav